For the first time, dairy producers have a choice in internal teat sealants, and new Lockout™ comes with advantages, like a more ergonomic syringe design and a visible blue paste for easy identification during the removal process.
Boehringer Ingelheim (BI), the second largest animal health business in the world, added LOCKOUT internal teat sealant to its mastitis portfolio earlier this year. LOCKOUT is a non-antibiotic paste that creates an immediate physical barrier against mastitis-causing bacteria at the time of dry-off or in pre-fresh dairy heifers.
The creators of LOCKOUT incorporated features and improvements based on input from producers.
- It’s the first non-antibiotic teat sealant to have a visible blue paste that’s easy to distinguish from milk during removal.
- The ergonomic design, exclusively owned by BI, maximizes efficiency while minimizing hand discomfort with the syringe’s larger thumb pad, widened wings and compact size.
- Application is fast, easy and hygienic. LOCKOUT comes in single-dose syringes with an easy-to-remove cap, and a short tip designed to reduce the risk of introducing new bacteria during insertion.
- The quick-plunge advantage allows for quick and comfortable administration with a significantly shorter, half-inch plunger stroke to deliver a full 4-gram dose without air bubbles.
“The blue paste is a powerful differentiator,” said Dr. Linda Tikofsky, senior associate director of professional veterinary services at BI. “Because it’s easier to distinguish the sealant from milk, producers no longer have to worry about unnecessarily sending a cow to the hospital pen.”
Twenty-five percent of quarters remain open one week after dry-off, creating an opportunity for infection to occur.1 LOCKOUT simulates a cow’s natural first line of defense, the keratin plug, to seal the teat against harmful bacteria by providing a sterile, antibiotic-free barrier between the udder and its environment.
BI continues to stay at the forefront of innovation and provide producers with the right tools for disease prevention. LOCKOUT joins ToMORROW® (cephapirin benzathine) and
Dry-Clox® (cloxacillin benzathine) as part of the BI dry cow mastitis portfolio. To learn how to incorporate LOCKOUT into your herd’s mastitis protocol, talk to your veterinarian or BI representative or visit LockoutTeatSealant.com.
ABOUT BOEHRINGER INGELHEIM
Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 percent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
Boehringer Ingelheim Animal Health Business Unit
Boehringer Ingelheim is the second largest animal health business in the world. We are committed to creating animal well-being through our large portfolio of advanced, preventive healthcare products and services. With net sales of €3.9 billion and around 10,000 employees worldwide, we are present in more than 150 markets. For more information click here.
1 Ruegg P. Managing the dry period for quality, 2011